Gland Pharma Limited has informed the Exchange about change in Management
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Despite the headline mentioning a change in management, the filing actually concerns the appointment of Secretarial Auditors, not a management change. Gland Pharma's shareholders, at the 47th Annual General Meeting held on August 28, 2025, approved the appointment of M/s. RVR & Associates, a peer-reviewed firm of Practicing Company Secretaries, as the company's Secretarial Auditors. The appointment is for a term of five consecutive years, covering the period from the conclusion of the 47th AGM to the conclusion of the 52nd AGM. The firm is led by founding partner Mr. R. Venkata Ramana, who has over 20 years of experience in secretarial audits, corporate compliance, FEMA, and M&A matters.
This is a routine corporate governance filing and is unlikely to have any material impact on the stock price or shareholder interests. Shareholders have simply formalised the appointment of the secretarial auditor that the board had already approved in May 2025.